
Unprecedented Data and Insights
Seeing the Whole Picture of Cells in Disease
What distinguishes our approach is our deep single-cell genomic analysis of meticulously curated datasets from human tissue samples. Celsius is the first company to do this at scale. Using a multidisciplinary approach, we translate these deep insights into precision therapeutics for inflammatory disease.

Designing More Precise Development Programs
The ability to better understand human cells in a disease state means that we can design more targeted drug development programs around newly-defined patient subsets and build a broad therapeutics pipeline.
